Clearside Biomedical Announces Fourth Patent Allowance in the U.S. Related To Proprietary Microneedle Drug Delivery Methods and Devices
Source: Clearside Biomedical Inc.
Friday, September 05, 2014 | Practice Development
Clearside Biomedical announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,808,225 titled, "Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle." This is the fourth patent allowance in the U.S. related to its proprietary microneedle drug delivery methods and devices, according to a company news release.
U.S. Patent No. 8,808,225 provides exclusivity for the administration of any drug to an eye of a patient by inserting a hollow microneedle into the patient’s eye and infusing the drug into the suprachoroidal space of the patient’s eye. The patent, exclusively licensed to Clearside, is the fourth generated from Clearside’s alliance with the Georgia Tech Research Corporation and Emory University.
In April 2011, June 2012 and January 2014, the U.S. Patent and Trademark Office issued method and device patents covering the company's drug delivery methods and devices for carrying out the methods.
You must be logged in to leave a comment.